Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 in heart failure with reduced or mildly reduced ejection fraction
NCT06142383Phase 2Terminated
- Sponsor
- Novartis
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of xxb750 in heart failure (HF), sponsored by Novartis. Started Dec 2023; status: terminated.
02
Drugs
xxb750
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06142383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06142383.